Extracellular ATP activates MAP kinase cascades through a P2Y purinergic receptor in the human intestinal Caco-2 cell line

Biochimica et Biophysica Acta - General Subjects

Volumn 1790, Issue 12, 2009, Pages 1651-1659

  Buzzi, Natalia ^a   Bilbao, Paola Scodelaro ^a   Boland, Ricardo ^a   de Boland, Ana Russo ^a  

^a UNIVERSIDAD NACIONAL DEL SUR   (Argentina)

Author keywords

ATP; Caco 2 cells; MAPKs; P2Y receptors

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN TYROSINE KINASE; PURINERGIC P2Y RECEPTOR; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; STRESS ACTIVATED PROTEIN KINASE 1;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CANCER CELL; CELL STIMULATION; CELL STRAIN CACO 2; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPECTROFLUOROMETRY;

ADENOSINE TRIPHOSPHATE; CACO-2 CELLS; CELL LINE, TUMOR; ENTEROCYTES; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR SPACE; HUMANS; INTESTINES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTORS, PURINERGIC P2; TIME FACTORS;

EID: 71549142293     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2009.10.005     Document Type: Article

References (55)

1. Abbracchio M.P., and Burnstock G. Purinergic signalling: pathophysiological roles. Jpn. J. Pharmacol. 78 (1998) 113-145
2. Ralevic V., and Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50 (1998) 413-492
3. 14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol. Sci. 24 (2003) 52-55
4. Communi D., Gonzalez N.S., Detheux M., Brezillon S., Lannoy V., Parmentier M., and Boeynaems J.M. Identification of a novel human ADP receptor coupled to Gi. J. Biol. Chem. 276 (2001) 41479-41485
5. Jacobson K.A., King B.F., and Burnstock G. Pharmacological characterization of P2 (nucleotide) receptors. Cell Transm. 16 (2002) 1-23
6. Erlinge D. Extracellular ATP: a growth factor for vascular smooth muscle cells. Gen. Pharmacol. 31 (1998) 1-8
7. Coutinho-Silva R., Stahl L., Cheung K.K., Enes de Campos N., de Oliveira Souza C., Ojcius D.M., and Burnstock G. P2X and P2Y purinergic receptors on human intestinal epithelial carcinoma cells: effects of extracellular nucleotides on apoptosis and cell proliferation. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) 1024-1035
8. Nylund G., Hultman L., Nordgren S., and Delbro D.S. P2Y2- and P2Y4 purinergic receptors are over-expressed in human colon cancer. Auton. Autacoid Pharmacol. 27 (2007) 79-84
9. Adjei A.A., Morioka T., Ameho C.K., Yamauchi K., Kulkarni A.D., Al Mansouri H.M., Kawajiri A., and Yamamoto S. Nucleoside-nucleotide free diet protects rat colonic mucosa from damage induced by trinitrobenzene sulphonic acid. Gut 39 (1996) 428-433
10. Kottgen M., Loffler T., Jacobi C., Nitschke R., Pavenstadt H., Schreiber R., Frische S., Nielsen S., and Leipziger J. P2Y6 receptor mediates colonic NaCl secretion via differential activation of cAMP-mediated transport. J. Clin. Invest. 111 (2003) 371-379
11. Grbic D.M., Degagné E., Langlois C., Dupuis A.A., and Gendron F.P. Intestinal inflammation increases the expression of the P2Y6 receptor on epithelial cells and the release of CXC chemokine ligand 8 by UDP. J. Immunol. 180 (2008) 2659-2668
12. Leleiko N.S., Walsh M.J., and Abraham S. Gene expression in the intestine; the effect of dietary nucleotides. In: Barness L.A., DeVivo D.C., Kaback M.M., Morrow G., Oski F.A., and Rudolph A. (Eds). Advances in Paediatrics (1995), Mosby Yearbook, St Louis 145-169
13. Dezaki K., Tsumura T., Maeno E., and Okada Y. Receptor-mediated facilitation of cell volume regulation by swelling-induced ATP release in human epithelial cells. Jpn. J. Physiol. 50 (2000) 235-241
14. Abbrachio M.P., Burnstock G., Boeynaems J.M., Barnard E.A., Boyer J.L., Kennedy C.H., Knight G.E., Fumagalli M., Gachet C., Jacobson K.A., and Weisman G.A. International Union of Pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol. Rev. 58 (2006) 281-341
15. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81 (2001) 807-869
16. Chang C.I., Xu B.E., Akella R., Cobb M.H., and Godsmith E.J. Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3. Mol. Cell 9 (2002) 1241-1249
17. Tanoue T., Adachi M., Moriguchi T., and Nishida E. A conserved docking motif in MAP kinases common to substrates, activators and regulators. Nat. Cell Biol. 2 (2000) 110-116
18. Whitmarsh A.J., and Davis R.J. Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals. Trends Biochem. Sci. 23 (1998) 481-485
19. Chantret I., Barbat A., Dussaulx E., Brattain M.G., and Zweibaum A. Epithelial polarity, villin expression, and enterocytic differentiation of cultured human colon carcinoma cells: a survey of twenty cell lines. Cancer Res. 48 (1988) 1936-1942
20. Bradford M. A rapid and sensitive method for quantification of microgram quantities of proteins utilizing the principle of protein binding. Anal. Biochem. 72 (1976) 248-254
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage. Nature 227 (1970) 680-685
22. Fries J.E., Wheeler-Schilling T.H., Guenther E., and Kholer K. Expression of P2Y1, P2Y2, P2Y4 and P2Y6 receptor subtypes in the rat retina. Inv. Ophthalmol. Vis. Sci. 45 (2004) 3410-3417
23. McAlroy H.L., Ahmed S., Day S.M., Baines D.L., Wong H.Y., Yip C.Y., Ko W.H., Wilson S.M., and Collett A. Multiple P2Y receptor subtypes in the apical membranes of polarized epithelial cells. Br. J. Pharmacol. 131 (2000) 1651-1658
24. Li Z., Hosoi Y., Cai K., Tanno Y., Matsumoto Y., Enomoto A., Morita A., Nakagawa K., and Miyagawa K. Src tyrosine kinase inhibitor PP2 suppresses ERK1/2 activation and epidermal growth factor receptor transactivation by X-irradiation. Biochem. Biophys. Res. Commun. 341 (2006) 363-368
25. Botelho L.H.P., Rothermel J.D., Coombs R.V., and Jastorff M. cAMP analog antagonists of cAMP action. Methods Enzymol. 159 (1988) 159-172
26. Alessi D.R., and The protein kinase C. inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1β (Rsk-2) and p70 S6 kinase. FEBS Lett. 402 (1997) 121-123
27. Resnick M.B., Gallinger S., Wang H.H., and Odze R.D. Growth factor expression and proliferation kinetics in periampullary neoplasms in familial adenomatous polyposis. Cancer 76 (1995) 187-194
28. Shimada N., Suzuki J., Fujita J., Kawakami Y., Tsukakoshi H., Hosokawa M., and Sato N. A comparative study of nucleolar organizer region, proliferating cell nuclear antigen and epidermal growth factor receptor staining in colon tumors. J. Gastroenterol. Hepatol. 13 (1998) 794-800
29. Malecka-Panas E., Kordek R., Biernat W., Tureaud J., Liberski P.P., and Majumdar A.P. Differential activation of total and EGF receptor (EGFR) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology 44 (1997) 435-440
30. Levitzki A., and Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267 (1995) 1782-1788
31. Raman M., Chen W., and Cobb M.H. Differential regulation and properties of MAPKs. Oncogene 26 (2007) 3100-3112
32. 2+ in breast cancer (MCF-7) cells. Arch. Biochem. Biophys. 466 (2007) 15-23
33. 2+ release, stress activatedand L-voltage-dependent calcium influx, PKC and Src kinases. Arch. Biochem. Biophys. 477 (2008) 244-252
34. Sabapathy K., Hochedlinger K., Nam S.Y., Bauer A., Karin M., and Wagner E.F. Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. Mol. Cell 15 (2004) 713-725
35. Burnstock G. Purinergic signalling. Br. J. Pharmacol. 147 (2006) 172-181
36. Erb L., Liao Z., Seye C.I., and Weisman G.A. P2 receptors: intracellular signaling. Pflugers Arch. Eur. J. Physiol. 452 (2006) 552-562
37. Lustig K.D., Shiau A.K., Brake A.J., and Julius D. Expression cloning of an ATP receptor from mouse neuroblastoma cells. Proc. Natl. Acad. Sci. 90 (1993) 5113-5117
38. Lazarowski E.R., Watt W.C., Stutts M.J., Boucher R.C., and Harden T.K. Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br. J. Pharmacol. 116 (1995) 1619-1627
39. Schöfl C., Ponczek M., Mader T., Waring M., Benecke H., Von Zur Mühlen A., Mix H., Cornberg M., Böker K.H.W., Manns M.P., and Wagner S. Regulation of cytosolic free calcium concentration by extracellular nucleotides in human hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 276 (1999) 164-172
40. Kügelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol. Ther. 110 (2006) 415-432
41. 2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling. Mol. Pharmacol. 63 (2003) 1356-1363
42. Nylund G., Nordgren S., and Delbro D.S. Expression of P2Y2 purinoceptors in MCG 101 murine sarcoma cells, and HT-29 human colon carcinoma cells. Auton. Neurosci. 112 (2004) 69-79
43. Agell N., Bachs O., Rocamora N., and Villalonga P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell. Signal. 14 (2002) 649-654
44. Soltoff S.P., Avraham H., Avraham S., and Cantley L.C. Activation of P2Y2 receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C. J. Biol. Chem. 273 (1998) 2653-2660
45. Montiel M., de la Blanca E.P., and Jimenez E. P2Y receptors activate MAPK/ERK through a pathway involving PI3K/PDK1/PKC-zeta in human vein endothelial cells. Cell. Physiol. Biochem. 18 (2006) 123-134
46. Katz S., Boland R., and Santillán G. Modulation of ERK 1/2 and p38 MAPK signaling pathways by ATP in osteoblasts: Involvement of mechanical stress-activated calcium influx, PKC and Src activation. Int. J. Biochem. Cell Biol. 38 (2006) 2082-2091
47. Communi D., Govaerts C., Parmentier M., and Boeynaems J.M. Cloning of a human purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J. Biol. Chem. 272 (1997) 31969-31973
48. van der Weyden L., Adams D.J., Luttrell B.M., Conigrave A.D., and Morris M.B. Pharmacological characterisation of the P2Y11 receptor in stably transfected haematological cell lines. Mol. Cell. Biochem. 213 (2000) 75-81
49. Höpfner M., Maaser K., Barthel B., von Lampe B., Hanski C., Riecken E.O., Zeitz M., and Scherübl H. Growth inhibition and apoptosis induced by P2Y2 receptors in human colorectal carcinoma cells: involvement of intracellular calcium and cyclic adenosine monophosphate. Int. J. Colorectal Dis. 16 (2001) 154-166
50. Post S.R., Jacobson J.P., and Insel P.A. P2 purinergic receptor agonists enhance cAMP production in Madin-Darby canine kidney epithelial cells via an autocrine/paracrine mechanism. J. Biol. Chem. 271 (1996) 2029-2032
51. i elevation can substitute for receptor activation. J. Biol. Chem. 273 (1998) 23110-23117
52. Liu J., Liao Z., Camden J., Griffin K.D., Garrad R.C., Santiago-Pérez L.I., González F.A., Seye C.h., Weisman G.A., and Erb L. Src homology 3 binding sites in the P2Y2 nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors. J. Biol. Chem. 279 (2004) 8212-8218
53. Prenzel N., Zwick E., Daub H., Leserer M., Abraham R., Wallasch C., and Ullrich A. EGF receptor transactivation by G-protein coupled receptors requires metalloproteinase cleavage of proHBEGF. Nature 402 (1999) 884-888
54. Milenkovic I., Weick M., Wiedemann P., Reichenbach A., and Bringmann A. P2Y receptor-mediated stimulation of Müller glial cell DNA synthesis: dependence on EGF and PDGF receptor transactivation. IOVS 44 (2003) 1211-1220
55. Pai R., Soreghan B., Szabo I.L., Pavelka M., Baatar D., and Tarnawski A.S. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8 (2002) 289-293